Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
168
Participants
Timeline
Start Date
October 19, 2020
Primary Completion Date
November 9, 2022
Study Completion Date
November 9, 2022
Conditions
Healthy
Interventions
DRUG
Denosumab
60 mg, single-dose
Trial Locations (2)
07103
Biotrial, Newark
Unknown
Biotrial Rennes, Rennes
All Listed Sponsors
lead
Samsung Bioepis Co., Ltd.
INDUSTRY
NCT04621318 - Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity Study of SB16 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter